Skip to main content

Richard A. Scolyer, M.D., Clinical Team LeaderMelanoma Institute of Australia

Area of Research: Lung Cancer, Breast Cancer, Melanoma

Dr. Scolyer, along with Mark John Smyth, Ph.D., FAHMS, Georgina V. Long, M.D., Ph.D., John Stagg, Ph.D., and Scott J. Antonia, M.D., Ph.D., is leading efforts to address the impact of adenosine in the tumor environment, by targeting the CD73 receptor that helps produce adenosine as well as the A2A receptor (A2AR) that is activated by adenosine.

Their project consists of four parts: assessing the effectiveness of anti-CD73 and anti-A2AR treatments in combination with anti-PD-1/PD-L1 therapy in mouse cancer models; determining the prognostic value of CD73 in mouse cancer models; analyzing expression of A2AR in tumor-infiltrating immune cells from humans; and evaluating the effects of various combination therapies on human tumor-infiltrating immune cells. Overall, their results should shed light on how adenosine promotes specific cancerous behaviors as well as approaches that can be used to effectively address them.

Projects and Grants

Targeting adenosine in the tumor microenvironment

Melanoma Institute of Australia | Breast Cancer, Lung Cancer, Melanoma | 2015

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Top